Episode 59
Biotech Hangout
00:00
The FDA's Negative Response to the Sorep to Adcom
I was tracking a little bit earlier, but it sounded like the FDA was sounding pretty negative. I didn't hear much afterwards from the advisors. What have you guys been hearing? It seemed a little almost premature for the FDA to raise that kind of a concern. There's really nothing, nothing imminently emerging that would require AV delivery and that could generate even better results as well.
Transcript
Play full episode
